Was in phase II/III trial with a SERCa2a gene therapy to help heart failure patients hearts to beat without increasing the oxygen consumption (NASDAQ:CLDN)
Patches for desensitization of food allergy using epicutaneous delivery in clinical trials.
Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.
Sold to Gilead in 2015
Develops a biologic to treat moderate to severe form of the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness
Sold to Horizon in 2017
Platform with natural and modified Botulinium toxins for cell secretion inhibition.
Sold to Ipsen in 2013
Develops VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint. VTS-270 is in a pivotal phase II/III clinical trial to treat patients with Niemann-Pick Disease Type C.
Sold to Sucampo Pharmaceuticals, Inc. in 2017
Develops dermatological drugs, the lead being an H4 receptor antagonist in phase IIa for Atopic Dermatitis and soon phase IIa for Psoriasis.
Sold to Novartis in 2016